While the addition of IFN-α to a TKI in this study did not prolong PFS or OS, IFN-α may still have a role in CML treatment, e.g., in the maintenance of remission after TKI discontinuation [55]. This evidence concerns the gene IFNA2 and chronic myelogenous leukemia, BCR-ABL1 positive.